证券代码：002737 证券简称：葵花药业 公告编号：2025-073 葵花药业集团股份有限公司 关于复方聚乙二醇(3350)电解质散 获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 9、适应症：（1）用于治疗 1 岁至 11 岁儿童慢性便秘。（2）用于治疗 5 岁 至 11 岁儿童粪便嵌塞，即顽固性便秘伴直肠和/或结肠粪块堆积。 1 1、药品通用名称：复方聚乙二醇（3350）电解质散 2、主要成份：聚乙二醇 3350、氯化钠、氯化钾、碳酸氢钠 3、申请事项：药品注册(境内生产) 4、规格：6.9g/袋 5、注册分类：化学药品 3 类 6、处方药/非处方药：处方药 7、药品批准文号：国药准字 H20255906 10、上市许可持有人及生产企业：葵花药业集团（唐山）生物制药有限公司 二、风险提示 复方聚乙二醇（3350）电解质散取得《药品注册证书》后，公司将加速推进 新产品的量产与市场投放，进一步拓展产品矩阵，优化产品结构布局，依托品牌 资源优势，提升市场竞争力。药品上市推广受国家政策、市场环境等因素影响， 销售业绩具有不确定性。敬请广大 ...

复方聚乙二醇(3350)电解质散取得《药品注册证书》后，公司将加速推进新产品的量产与市场投放，进 一步拓展产品矩阵，优化产品结构布局，依托品牌资源优势，提升市场竞争力。 葵花药业（002737）(002737.SZ)发布公告，公司子公司于近日收到国家药品监督管理局下发的关于复 方聚乙二醇(3350)电解质散获批注册的药品注册证书。 ...

葵花药业11月14日公告，公司子公司葵花药业集团（唐山）生物制药有限公司获得国家药品监督管理局 核准签发的复方聚乙二醇（3350）电解质散《药品注册证书》。该药品主要成份为聚乙二醇3350、氯化 钠、氯化钾、碳酸氢钠，规格为6.9g/袋，注册分类为化学药品3类，为处方药。 ...

格隆汇11月14日丨葵花药业(002737.SZ)公布，子公司于近日收到国家药品监督管理局下发的关于复方 聚乙二醇（3350）电解质散获批注册的药品注册证书，适应症：（1）用于治疗1岁至11岁儿童慢性便 秘。（2）用于治疗5岁至11岁儿童粪便嵌塞，即顽固性便秘伴直肠和/或结肠粪块堆积。 ...

葵花药业公告，子公司于近日收到国家药品监督管理局下发的关于复方聚乙二醇（3350）电解质散获批 注册的药品注册证书。该药品主要成分为聚乙二醇3350、氯化钠、氯化钾、碳酸氢钠，规格为6.9g/ 袋，注册分类为化学药品3类，为处方药。药品批准文号为国药准字H20255906，适应症为治疗1岁至11 岁儿童慢性便秘，以及5岁至11岁儿童粪便嵌塞。上市许可持有人及生产企业为葵花药业集团（唐山） 生物制药有限公司。 ...

（文章来源：证券日报） 证券日报网讯葵花药业11月12日在互动平台回答投资者提问时表示，截至2025年11月10日，公司股东人 数为5.3万户。 ...

Core Viewpoint - Recently, Sunflower Pharmaceutical received a warning letter from the Heilongjiang Securities Regulatory Bureau due to violations related to related party transactions, which have contributed to a significant decline in the company's performance in 2024 [1][3]. Financial Performance - In the first three quarters of 2024, Sunflower Pharmaceutical's revenue decreased by 43.24% to approximately 1.684 billion yuan, while net profit fell by 105.72% to about -33.54 million yuan, and the non-recurring net profit dropped by 117.68% to around -81.39 million yuan [2]. - The third quarter alone saw a revenue decline of 14.9% to about 374 million yuan, with net profit down 214.27% to approximately -115 million yuan, marking the first quarterly loss since the company went public [2][5]. - The company's cash flow from operating activities turned negative in the third quarter, amounting to approximately -130 million yuan, after being positive in the first half of the year [4]. Business Operations - Sunflower Pharmaceutical primarily operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drugs, and health products, with key revenue sources including children's medicine and liver protection products [4]. - The company has been facing significant sales declines, attributed to seasonal factors affecting respiratory products and increased costs due to fluctuations in raw material prices [5][6]. Related Party Transactions - The warning letter specifically addressed related party transactions involving a wholly-owned subsidiary and an associated entity, which were not disclosed as required, leading to administrative measures against the company and its executives [1][3]. Research and Development - R&D expenditures have been decreasing, with a 3.51% decline in 2024 to about 124 million yuan, representing 3.67% of revenue, and a 16.78% drop in the first three quarters of 2024 to approximately 66.11 million yuan [7]. - The reduction in R&D investment raises concerns about the company's ability to innovate and sustain growth, especially as it aims to achieve a sales target of 10 billion yuan by 2028 [7]. Marketing and Sales Strategy - Sunflower Pharmaceutical has historically relied on advertising for sales, with sales expenses reaching 1.366 billion yuan in 2023, accounting for about 24% of revenue [8]. - In 2024, the company implemented cost control measures, resulting in a 68.46% reduction in sales expenses to approximately 431 million yuan, which accounted for about 12.76% of revenue [8].

Core Viewpoint - As of October 31, 2025, the number of shareholders for Kweichow Moutai (002737) is projected to reach 53,000 households [1] Summary by Category - **Company Information** - Kweichow Moutai has indicated that it will have 53,000 shareholders by the end of October 2025 [1]

Core Viewpoint - The article highlights the challenges faced by葵花药业, including significant financial losses and regulatory scrutiny, particularly related to its marketing practices and reliance on OEM products, while also addressing the misleading promotion of its products aimed at height enhancement for young consumers [1][3][25]. Group 1: Company Overview and Financial Performance - 葵花药业 has reported its first loss since going public, with a net profit decline of 105.72% in the first three quarters of 2025, amounting to a loss of 335.39 million yuan [3][25]. - The company's revenue for the first three quarters of 2025 was 1.684 billion yuan, a decrease of 43.24% year-on-year, with a third-quarter revenue of 374 million yuan, down 14.9% [25][26]. - Total assets decreased by 12.06% to 5.123 billion yuan, and cash reserves dropped by 34.10% due to declining sales [25][27]. Group 2: Regulatory Issues and Marketing Practices - The Heilongjiang Securities Regulatory Bureau issued a warning letter to葵花药业 regarding a 32.38 million yuan related party transaction with海维生物, which was not disclosed properly [3][4]. - The company has been criticized for its reliance on OEM products, with many of its offerings produced by海维生物, which has faced quality control issues in the past [7][8]. -葵花药业's marketing strategy, particularly through live streaming, has been scrutinized for promoting products with unsubstantiated claims about height enhancement, misleading consumers about the efficacy of its calcium supplements [9][11][21]. Group 3: Product and Market Strategy -葵花药业's calcium supplement, marketed as a height-enhancing product, is being promoted in a way that suggests it can benefit individuals up to 26 years old, despite scientific evidence indicating that height is primarily determined by genetics and growth hormone levels [9][21]. - The company has faced backlash from consumers who reported no results from the product, with some labeling it as a "智商税" (intelligence tax) for its perceived ineffectiveness [16][19]. -葵花药业's traditional marketing approach of heavy advertising is becoming less effective in the current market environment, leading to a significant reduction in sales and brand visibility [29].

Core Viewpoint - The announcement indicates that the company has received a registration acceptance notice from the National Medical Products Administration for the marketing authorization of Fusidic Acid Cream [2] Group 1 - The company's wholly-owned subsidiary, Harbin Kuihua Pharmaceutical Co., Ltd., is involved in the application process for Fusidic Acid Cream [2] - The registration acceptance notice is a significant step towards obtaining marketing approval for the product [2]